Holen Sie sich die Stockscreener-App
176.16
0.53%
1.065
Beigene Ltd Adr Aktie (ONC) Neueste Nachrichten
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - GlobeNewswire Inc.
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Beigene directors sell shares worth $194.2 million - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces passing of board member Donald Glazer - Investing.com
BeiGene stock momentum builds on Brukinsa success, says JPMorgan's Fye - Investing.com
BeiGene CEO John Oyler sells shares worth over $3.75 million - Investing.com
BeiGene's SVP sells shares worth nearly $285k - Investing.com
BeiGene executive sells over $1.1m in company shares - Investing.com
CCBI Lowers BEIGENE (06160.HK) TP to $140, Solid 2Q Results Expected - AASTOCKS.com
Nomura Raises BEIGENE (06160.HK)'s TP to $158.37 and Rev. Forecast for FY24/FY25 - AASTOCKS.com
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why - Yahoo Finance
Primecap Odyssey Funds' 2023 Semiannual Letter - GuruFocus.com
Making it harder to "buy" China, Inc. - US-China Institute
What Happens to Your ETFs if Chinese ADRs Delist? - HK.Morningstar.com
Will We See a Slew of ADR Delistings? - HK.Morningstar.com
See What the Public Investment Fund Bought Recently Including Walmart and FedEx Stocks - Sovereign Wealth Fund Institute
BeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion - Yahoo Finance
BeiGene Ltd. Sponsored ADR to Host Earnings Call - AccessWire
8.61%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):